Previous Close | 62.48 |
Open | 61.95 |
Bid | 61.40 x 1000 |
Ask | 61.62 x 800 |
Day's Range | 61.29 - 62.40 |
52 Week Range | 57.17 - 74.12 |
Volume | |
Avg. Volume | 8,145,691 |
Market Cap | 77.529B |
Beta (5Y Monthly) | 0.38 |
PE Ratio (TTM) | 17.27 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 2.92 (4.67%) |
Ex-Dividend Date | Jun 14, 2022 |
1y Target Est | N/A |
Regulatory and other updates from Epizyme (MRNA) and Kezar (KZR) are a few key highlights from the biotech sector during the past week.
Gilead's (GILD) cell therapy, Yescarta, gets approval in Europe for a third indication- adult patients with relapsed or refractory follicular lymphoma after three or more lines of systemic therapy.
Gilead Sciences (GILD) closed at $62.21 in the latest trading session, marking a -0.99% move from the prior day.